The Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand and Lung Cancer Still Following the Right TRAIL?

Emmet McGrath

Research output: Contribution to journalEditorial

9 Citations (Scopus)

Abstract

Tumor necrosis factor-related apoptosis-inducing ligand is a type II membrane-bound protein whose C-terminal extracellular domain shows clear homology to other tumor necrosis factor family members. It is constitutively expressed on macrophages, T cells, natural killer cells, and dendritic cells and selectively kills transformed cells leaving most of the normal cells alone. This selectivity has led to great interest in it use as a therapeutic agent for the treatment of malignancy. In this review, this critical pathway is described, highlighting its mechanistic manipulation for therapeutic benefit and the recent phase I and II trials in lung cancer that have been performed or are currently ongoing are also discussed.
Original languageEnglish
Pages (from-to)983-987
Number of pages5
JournalJournal of Thoracic Oncology
Volume6
Issue number6
DOIs
Publication statusPublished - 1 Jun 2011

Keywords

  • Small cell lung cancer
  • Non-small cell lung cancer
  • Apoptosis
  • TNF-related apoptosis-inducing ligand (TRAIL)
  • Clinical trials

Fingerprint

Dive into the research topics of 'The Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand and Lung Cancer Still Following the Right TRAIL?'. Together they form a unique fingerprint.

Cite this